SCOPUS 정보 검색 플랫폼

Infectious Diseases in Clinical Practice

Volumn 14, Issue 5, 2006, Pages 327-328

Early-onset rhabdomyolysis associated with daptomycin

(3) Edwards, Charles M a King, Kelli a Garcia, Roberto J a

a UNIVERSITY OF SOUTH FLORIDA (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; COTRIMOXAZOLE; CREATINE KINASE; DAPTOMYCIN; HYDROCODONE BITARTRATE PLUS PARACETAMOL; VANCOMYCIN;

ACUTE TOXICITY; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL ARTHRITIS; BACTERIAL VIRULENCE; CASE REPORT; CREATINE KINASE BLOOD LEVEL; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG INDUCED DISEASE; FEMALE; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MYALGIA; NUCLEAR MAGNETIC RESONANCE IMAGING; RHABDOMYOLYSIS; ROTATOR CUFF INJURY; SHOULDER PAIN; SURGICAL INFECTION; SURGICAL WOUND;

EID: 33748768444 PISSN: 10569103 EISSN: None Source Type: Journal
DOI: 10.1097/01.idc.0000219054.28051.b4 Document Type: Article

Times cited : (12)

References (8)

1
- 19644388857
- Daptomycin: A novel cyclic lipopeptide antimicrobial
- Schriever CA, Fernandez C, Rodvold KA, et al. Daptomycin: a novel cyclic lipopeptide antimicrobial. Am J Health Syst Pharm. 2005;62:1145-1158.
- (2005) Am J Health Syst Pharm , vol.62 , pp. 1145-1158
- Schriever, C.A.¹ Fernandez, C.² Rodvold, K.A.³

2
- 2942665465
- The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections
- Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38:1673-1681.
- (2004) Clin Infect Dis , vol.38 , pp. 1673-1681
- Arbeit, R.D.¹ Maki, D.² Tally, F.P.³

3
- 0037214897
- Linezolid, quinupristin/dalfopristin, and daptomycin in dermatology
- Wesson KM, Lerner DS, Silverberg NB, et al. Linezolid, quinupristin/dalfopristin, and daptomycin in dermatology. Clin Dermatol. 2003;21:64-69.
- (2003) Clin Dermatol , vol.21 , pp. 64-69
- Wesson, K.M.¹ Lerner, D.S.² Silverberg, N.B.³

4
- 1842503232
- Daptomycin: Another novel agent for treating infections due to drug-resistant Gram-positive pathogens
- Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant Gram-positive pathogens. Clin Infect Dis. 2004;38:994-1000.
- (2004) Clin Infect Dis , vol.38 , pp. 994-1000
- Carpenter, C.F.¹ Chambers, H.F.²

5
- 0037378761
- Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects
- Dvorchik BH, Brazier D, DeBruin MF, et al. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother. 2003;47(4):1318-1323.
- (2003) Antimicrob Agents Chemother , vol.47 , Issue.4 , pp. 1318-1323
- Dvorchik, B.H.¹ Brazier, D.² DeBruin, M.F.³

6
- 7044223098
- Muscle pain associated with daptomycin
- Veligandla SR, Louie KR, Malesker MA, et al. Muscle pain associated with daptomycin. Ann Pharmacother. 2004;38(11):1860-1862.
- (2004) Ann Pharmacother , vol.38 , Issue.11 , pp. 1860-1862
- Veligandla, S.R.¹ Louie, K.R.² Malesker, M.A.³

7
- 17444413797
- Severe myopathy and possible hepatotoxicity related to daptomycin
- Echevarria K, Datta P, Cadena J, et al. Severe myopathy and possible hepatotoxicity related to daptomycin. J Antimicrob Chemother. 2005;55(4):599-600.
- (2005) J Antimicrob Chemother , vol.55 , Issue.4 , pp. 599-600
- Echevarria, K.¹ Datta, P.² Cadena, J.³

8
- 2942640370
- Moderate liver impairment has no influence on daptomycin pharmacokinetics
- Dvorchik B. Moderate liver impairment has no influence on daptomycin pharmacokinetics. J Clin Pharmacol. 2004;44:715-722.
- (2004) J Clin Pharmacol , vol.44 , pp. 715-722
- Dvorchik, B.¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.